Global Anterior Horn Cell Disease Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anterior Horn Cell Disease Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
The procedure of achieving an accurate balance between the available feed ingredients is referred to as feed testing. The primary goal of the feed program is to reduce the level of contamination in animal feedstock. Feed ingredient nutrient content information is required for successful feed testing. Pesticides, mycotoxin, minerals, pathogens, metals, antibiotics, and drugs are tested in feed, among other feed ingredients, to determine the absence of contaminants that can cause toxicity, foodborne diseases, and poisoning.
Anterior Horn Cell Disease Treatment report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anterior Horn Cell Disease Treatment market is projected to reach US$ 956.5 million in 2029, increasing from US$ 713 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Demand from Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy are the major drivers for the industry.
Numerous studies have shown that older adults are more susceptible to the disease. According to United Nations data, in 2021, there will be 761 million people aged 65 and over in the world, and this number will increase to 1.6 billion by 2050. The population aged 80 and over is growing faster. This increases the incidence of the disease and expands the growth of the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anterior Horn Cell Disease Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Sanofi
Novartis AG
Mitsubishi Chemical Group Corporation
BrainStorm Cell Limited
Ionis Pharmaceuticals
Genervon Biopharmaceuticals, LLC
Bausch Health Companies Inc
F. Hoffmann-La Roche Ltd
Treeway B.V
CYTOKINETICS
AB Science
ADVANZ PHARMA
Biogen
Orphazyme
KRIGLE PHARMA, INC
Aquestive Therapeutics, Inc
Apotex Inc
Segment by Type
Riluzole
Edaravone
Glutamate Receptor Antagonist
Other
Amyotrophic Lateral Sclerosis
Spinal Muscular Atrophy
Multifocal Motor Neuropathy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anterior Horn Cell Disease Treatment market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Anterior Horn Cell Disease Treatment introduction, etc. Anterior Horn Cell Disease Treatment Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Anterior Horn Cell Disease Treatment market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Anterior Horn Cell Disease Treatment report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anterior Horn Cell Disease Treatment market is projected to reach US$ 956.5 million in 2029, increasing from US$ 713 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Demand from Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy are the major drivers for the industry.
Numerous studies have shown that older adults are more susceptible to the disease. According to United Nations data, in 2021, there will be 761 million people aged 65 and over in the world, and this number will increase to 1.6 billion by 2050. The population aged 80 and over is growing faster. This increases the incidence of the disease and expands the growth of the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anterior Horn Cell Disease Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Sanofi
Novartis AG
Mitsubishi Chemical Group Corporation
BrainStorm Cell Limited
Ionis Pharmaceuticals
Genervon Biopharmaceuticals, LLC
Bausch Health Companies Inc
F. Hoffmann-La Roche Ltd
Treeway B.V
CYTOKINETICS
AB Science
ADVANZ PHARMA
Biogen
Orphazyme
KRIGLE PHARMA, INC
Aquestive Therapeutics, Inc
Apotex Inc
Segment by Type
Riluzole
Edaravone
Glutamate Receptor Antagonist
Other
Segment by Application
Amyotrophic Lateral Sclerosis
Spinal Muscular Atrophy
Multifocal Motor Neuropathy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anterior Horn Cell Disease Treatment market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Anterior Horn Cell Disease Treatment introduction, etc. Anterior Horn Cell Disease Treatment Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Anterior Horn Cell Disease Treatment market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices